Nonmyeloablative chemotherapy followed by T-cell adoptive transfer and dendritic cell-based vaccination results in rejection of established melanoma

Journal of Immunotherapy

Volumn 31, Issue 4, 2008, Pages 402-412

  Koike, Nobusada ^a   Pilon Thomas, Shari ^a   Mulé, James J ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

Dendritic cells; Immunotherapy; Lymphopenia

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DENDRITIC CELL VACCINE; FLUDARABINE; GAMMA INTERFERON; HERMES ANTIGEN; L SELECTIN; OVALBUMIN;

ADOPTIVE TRANSFER; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CD8+ T LYMPHOCYTE; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; DISEASE MODEL; DRUG EFFICACY; DRUG MECHANISM; GENE EXPRESSION; GRAFT REJECTION; IMMUNIZATION; LYMPHOCYTOPENIA; MELANOMA; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR REGRESSION; VACCINATION;

ADOPTIVE TRANSFER; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DENDRITIC CELLS; IMMUNOLOGIC MEMORY; INTERFERON TYPE II; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; VIDARABINE; WHOLE-BODY IRRADIATION;

EID: 42649085033     PISSN: 15249557     EISSN: None     Source Type: Journal    
DOI: 10.1097/CJI.0b013e31816cabbb     Document Type: Article

References (45)

1. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol. 1991;9:271-296.
2. Cella M, Sallusto F, Lanzavecchia A. Origin, maturation and antigen presenting function of dendritic cells. Curr Opin Immunol. 1997;9:10-16.
3. Cohen PJ, Cohen PA, Rosenberg SA, et al. Murine epidermal Langerhans cells and splenic dendritic cells present tumor-associated antigens to primed T cells. Eur J Immunol. 1994;24:315-319.
4. Nair SK, Snyder D, Rouse BT, et al. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int J Cancer. 1997;70:706-715.
5. Nouri-Shirazi M, Banchereau J, Bell D, et al. Dendritic cells capture killed tumor cells and present their antigens to elicit tumor-specific immune responses. J Immunol. 2000;165:3797-3803.
6. Kotera Y, Shimizu K, Mulé JJ. Comparative analysis of necrotic and apoptotic tumor cells as a source of antigen(s) in dendritic cell-based immunization. Cancer Res. 2001;61:8105-8109.
7. Chang AE, Redman BG, Whitfield JR, et al. A phase I trial of tumor lysate-pulsed dendritic cells in the treatment of advanced cancer. Clin Cancer Res. 2002;8:1021-1032.
8. Geiger JD, Hutchinson RJ, Hohenkirk LF, et al. Vaccination of pediatric solid tumor patients with tumor lysate-pulsed dendritic cells can expand specific T cells and mediate tumor regression. Cancer Res. 2001;61:8513-8519.
9. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998;4:328-332.
10. Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. Annu Rev Immunol. 2007;25:267-296.
11. Finke JH, Zea AH, Stanley J, et al. Loss of T-cell receptor zeta chain and p56lck in T-cells infiltrating human renal cell carcinoma. Cancer Res. 1993;53:5613-5616.
12. Gattinoni L, Powell DJ Jr, Rosenberg SA, et al. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol. 2006;6:383-393.
13. Mulé JJ, Jones FR, Hellstrom I, et al. Selective localization of radiolabeled immune lymphocytes into syngeneic tumors. J Immunol. 1979;123:600-606.
14. Lugade AA, Moran JP, Gerber SA, et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol. 2005; 174:7516-7523.
15. + T cells. J Exp Med. 2005;202:907-912.
16. Dummer W, Niethammer AG, Baccala R, et al. T cell homeostatic proliferation elicits effective antitumor autoimmunity. J Clin Invest. 2002;110:185-192.
17. Cho BK, Rao VP, Ge Q, et al. Homeostasis-stimulated proliferation drives naive T cells to differentiate directly into memory T cells. J Exp Med. 2000;192:549-556.
18. Dudley ME, Wunderlich JR, Yang JC, et al. A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma. J Immunother. 2002;25:243-251.
19. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298:850-854.
20. Ma J, Wang YL, Hu HM, et al. Mechanism of augmented antitumor immunity in reconstituted lymphopenic mice immunized with melanoma vaccine. Zhonghua Zhong Liu Za Zhi. 2005;27:708-712.
21. Hu HM, Poehlein CH, Urba WJ, et al. Development of antitumor immune responses in reconstituted lymphopenic hosts. Cancer Res. 2002;62:3914-3919.
22. Ge Q, Palliser D, Eisen HN, et al. Homeostatic T cell proliferation in a T cell-dendritic cell coculture system. Proc Nat Acad Sci USA. 2002;99:2983-2988.
23. Asavaroengchai W, Kotera Y, Koike N, et al. Augmentation of antitumor immune responses after adoptive transfer of bone marrow derived from donors immunized with tumor lysate-pulsed dendritic cells. Biol Blood Marrow Transplant. 2004;10:524-533.
24. Bacci A, Montagnoli C, Perruccio K, et al. Dendritic cells pulsed with fungal RNA induce protective immunity to Candida albicans in hematopoietic transplantation. J Immunol. 2002;168:2904-2913.
25. Asavaroengchai W, Kotera Y, Mulé JJ. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc Nat Acad Sci USA. 2002;99: 931-936.
26. Petrus MJ, Williams JF, Eckhaus MA, et al. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant. 2000;6:182-189.
27. Ercolini AM, Ladle BH, Manning EA, et al. Recruitment of latent pools of high-avidity CD8(+) T cells to the antitumor immune response. J Exp Med. 2005;201:1591-1602.
28. Estin CD, Stevenson US, Hellstrom I, et al. Cyclophosphamide potentiates the antitumor activity of v-p97NY. Cell Immunol. 1989;120:126-131.
29. Goldrath AW, Bogatzki LY, Bevan MJ. Naive T cells transiently acquire a memory-like phenotype during homeostasis-driven proliferation. J Exp Med. 2000;192:557-564.
30. Tanchot C, Le Campion A, Martin B, et al. Conversion of naive T cells to a memory-like phenotype in lymphopenic hosts is not related to a homeostatic mechanism that fills the peripheral naive T cell pool. J Immunol. 2002;168:5042-5046.
31. Shimizu K, Fields RC, Redman BG, et al. Potentiation of immunologic responsiveness to dendritic cell-based tumor vaccines by recombinant interleukin-2. Can J Sci Am. 2000;6(suppl 1):S67-S75.
32. Ge Q, Hu H, Eisen HN, et al. Different contributions of thymopoiesis and homeostasis-driven proliferation to the reconstitution of naive and memory T cell compartments. Proc Nat Acad Sci USA. 2002;99:2989-2994.
33. Ma J, Urba WJ, Si L, et al. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur J Immunol. 2003;33:2123-2132.
34. Rapoport AP, Stadtmauer EA, Aqui N, et al. Restoration of immunity in lymphopenic individuals with cancer by vaccination and adoptive T-cell transfer. Nat Med. 2005;11:1230-1237.
35. La Gruta NL, Driel IR, Gleeson PA. Peripheral T cell expansion in lymphopenic mice results in a restricted T cell repertoire. Eur J Immunol. 2000;30:3380-3386.
36. Ge Q, Rao VP, Cho BK, et al. Dependence of lymphopenia-induced T cell proliferation on the abundance of peptide/MHC epitopes and strength of their interaction with T cell receptors. Proc Nat Acad Sci USA. 2001;98:1728-1733.
37. Ernst B, Lee DS, Chang JM, et al. The peptide ligands mediating positive selection in the thymus control T cell survival and homeostatic proliferation in the periphery. Immunity. 1999;11: 173-181.
38. + T cells confer superior antitumor immunity compared with effector memory T cells. Proc Nat Acad Sci USA. 2005;102:9571-9576.
39. + T-cell memory in tumor immunology and immunotherapy. Immunol Rev. 2006;211: 214-224.
40. Oehen S, Brduscha-Riem K. Naive cytotoxic T lymphocytes spontaneously acquire effector function in lymphocytopenic recipients: a pitfall for T cell memory studies? Eur J Immunol. 1999;29: 608-614.
41. Kieper WC, Jameson SC. Homeostatic expansion and phenotypic conversion of naive T cells in response to self peptide/MHC ligands. Proc Nat Acad Sci U S A. 1999;96:13306-13311.
42. + T cells in lymphopenic hosts. Immunity. 1999;11:183-190.
43. + T-cell memory and prime-boost response after dendritic-cell vaccination. Nat Med. 2005;11:748-756.
44. Sallusto F, Lenig D, Forster R, et al. Two subsets of memory T lymphocytes with distinct homing potentials and effector functions. Nature. 1999;401:708-712.
45. He H, Wisner P, Yang G, et al. Combined IL-21 and low-dose IL-2 therapy induces anti-tumor immunity and long-term curative effects in a murine melanoma tumor model. J Transl Med [Electronic Resource]. 2006;4:24.